InvestSMART

Medical Developments International Limited (ASX:MVP)

ALERT: Price-sensitive ASX Announcement for MVP
Current share price for MVP : $0.475 0.085 (21.79%)+
Announcement
Release
24 Jul 2026 8:24AM
Price at Release
$0.390
Full Release
download
Summary
Medical Developments International Limited reported a positive free cash flow for Q4 and the full fiscal year 2026. The company saw a significant increase in Penthrox revenue, with a 28% volume growth in Australian hospitals and an 18% growth in European markets. Penthrox's market was expanded with the approval of a paediatric label in the UK and all EU markets. The company's cash balance at the end of June 2026 was $21.4 million. Financial performance was bolstered by stronger demand and pricing strategies, despite challenges in respiratory product sales. Operating cash flow improved significantly compared to the previous year, and the company remains focused on strategic priorities, including expanding Penthrox's market penetration.
Key Points
  • Positive free cash flow reported for Q4 and full FY26.
  • Penthrox revenue increased by $5.4 million.
  • Penthrox volume growth of 28% in Australian hospitals.
  • European Penthrox volume grew by 18%.
  • Paediatric label for Penthrox approved in UK and EU.
  • Cash balance of $21.4 million as of June 30, 2026.
  • Group revenue for Q4 FY26 was $10.5 million.
  • Pain Management revenue for Q4 was $7.9 million.
  • Respiratory revenue decreased, but US prices increased.
  • Cash from operating activities was $3.0 million in Q4 FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.